+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 40Years +
All Genders
ID05988463

Safety and Dose-Escalation Study of Artesunate in Adults 40 and Older with Idiopathic Pulmonary Fibrosis

Led by Joseph C. Wu · Updated on 2026-08-11

15

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Idiopathic Pulmonary Fibrosis IPF is a chronic, progressive lung disease that causes scarring of lung tissue, leading to worsening shortness of breath, cough, and low oxygen levels. This study is a single-center, randomized, double-blinded, placebo-controlled trial evaluating the safety and tolerability of the drug artesunate in participants with IPF. The trial aims to test three different dose levels of artesunate and explore blood biomarkers and lung function changes related to treatment effects.

CONDITIONS

Brief Title

Dose-Escalation Study of Artesunate Patients With IPF

Research Team

J

Joseph Wu, M.D, Ph.D.

E

Evgenios Neofytou, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here